Innate Pharma SA (FR:IPH) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innate Pharma SA has appointed Jonathan Dickinson as the new CEO and Chairman of the Executive Board, beginning November 1, 2024. Dickinson, who brings extensive biotech and pharmaceutical experience, succeeds interim CEO Hervé Brailly, who will remain in an advisory role to ensure a smooth transition. This leadership change is expected to drive the company’s innovative immuno-oncology pipeline forward, potentially impacting its stock performance.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.

